Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
AI McCormack, JAH Wass… - European journal of …, 2011 - Wiley Online Library
Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …
tumours are associated with substantial morbidity and mortality. Treatment options are often …
[引用][C] Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
AI MCCORMACK, JAH WASS… - European journal of …, 2011 - pascal-francis.inist.fr
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
AI McCormack, JAH Wass… - European journal of …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Aggressive pituitary tumours are associated with substantial morbidity and
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
AI McCormack, JA Wass… - European Journal of …, 2011 - europepmc.org
Background Aggressive pituitary tumours are associated with substantial morbidity and
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
A McCormack, J Wass, AB Grossman - EUROPEAN JOURNAL OF …, 2011 - ora.ox.ac.uk
Background Aggressive pituitary tumours are associated with substantial morbidity and
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
[引用][C] Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
AI McCormack, JAH Wass, AB Grossman - European Journal of Clinical …, 2011 - cir.nii.ac.jp
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
AI McCormack, JAH Wass… - European Journal of …, 2011 - search.ebscohost.com
Abstract Eur J Clin Invest 2011; 41 (10): 1133-1148 Abstract Background Aggressive
pituitary tumours are associated with substantial morbidity and mortality. Treatment options …
pituitary tumours are associated with substantial morbidity and mortality. Treatment options …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
AI McCormack, JAH Wass, AB Grossman - European Journal of Clinical …, 2011 - infona.pl
Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …
tumours are associated with substantial morbidity and mortality. Treatment options are often …
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
A McCormack, J Wass, A Grossman - European journal of clinical …, 2011 - ora.ox.ac.uk
BACKGROUND: Aggressive pituitary tumours are associated with substantial morbidity and
mortality. Treatment options are often limited, and chemotherapy has been reserved as …
mortality. Treatment options are often limited, and chemotherapy has been reserved as …